Treosulfan (Ovastat)

General information

Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.
Route: IV, PO
Extravasation: irritant

Diseases for which it is used

• Ovarian cancer

History of changes in EMA indication

• 2019-06-20: Initial authorization as Trecondi
• Uncertain date: Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non malignant diseases, and in paediatric patients older than one month with malignant diseases.
• 2023-08-08: Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.

Also known as

• Brand names: Ovastat, Trecondi